Glenmark Pharmaceuticals Ltd has announced that its Swiss unit, Glenmark Pharmaceuticals SA, has received USD 15 Million as milestone fees from Forest Laboratories, its North American partner, for an anti-asthma drug Oglemilast molecule.
Both companies are working together to initiate additional studies for further longer term development of oglemilast, including a Phase II study in Asthma.
